Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Clinical Cancer Research

• Publication date

  1999-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 10499599
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Delivery Systems for Immunomodulatory Proteins and Peptides

  2012cited by this paper
• Inhaled interleukin-2 in combination with low-dose systemic interleukin-2 and interferon α in patients with pulmonary metastatic renal-cell carcinoma: effectiveness and toxicity of mainly local treatment

  2005cited by this paper
• GM‐CSF‐transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune‐compromised mice

  1999cited by this paper
• A Placebo-Controlled Study of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor Administered During and After Induction Treatment for De Novo Acute Myelogenous Leukemia in Elderly Patients

  1998cited by this paper
• The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone.

  1998cited by this paper
• Gene immunotherapy in murine acute myeloid leukemia: granulocyte-macrophage colony-stimulating factor tumor cell vaccines elicit more potent antitumor immunity compared with B7 family and other cytokine vaccines.

  1998cited by this paper
• Attenuated hematopoietic response to granulocyte-macrophage colony-stimulating factor in patients with acquired pulmonary alveolar proteinosis.

  1998influential reference
• Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients.

  1998cited by this paper
• Granulocyte-macrophage colony-stimulating factor in patients with neutropenic fever is potent after low-risk but not after high-risk neutropenic chemotherapy regimens: results of a randomized phase III trial.

  1998cited by this paper
• Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor.

  1998cited by this paper
• A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

  1998cited by this paper
• Aerosolized antibiotics in mechanically ventilated patients: delivery and response.

  1998cited by this paper
• Dose intensification of chemotherapy and the role of granulocyte colony stimulating factor and granulocyte macrophage colony stimulating factor in small cell lung cancer.

  1997cited by this paper
• Persistence of pulmonary pathology and abnormal lung function in IL-3/GM-CSF/IL-5 β c receptor-deficient mice despite correction of alveolar proteinosis after BMT

  1997cited by this paper
• Can molgramostim enhance the antitumor effects of cytotoxic drugs in patients with advanced sarcomas?

  1997cited by this paper
• Interleukin‐2 liposome inhalation therapy is safe and effective for dogs with spontaneous pulmonary metastases

  1997cited by this paper
• Dendritic cells: unique leukocyte populations which control the primary immune response.

  1997cited by this paper
• Sensitizing T-lymphocytes for adoptive immunotherapy by vaccination with wild-type or cytokine gene-transduced melanoma

  1997cited by this paper
• Nebulized Interleukin 2 Liposomes: Aerosol Characteristics and Biodistribution

  1997cited by this paper
• Overexpression of granulocyte-macrophage colony-stimulating factor induces pulmonary granulation tissue formation and fibrosis by induction of transforming growth factor-beta 1 and myofibroblast accumulation.

  1997cited by this paper
• Granulocyte-macrophage colony-stimulating factor improves immunological parameters in patients with refractory solid tumours receiving second-line chemotherapy: correlation with clinical responses.

  1997cited by this paper
• Gene Therapy with B7.1 and GM‐CSF Vaccines in a Murine AML Model

  1997cited by this paper
• Continuous infusion or subcutaneous injection of granulocyte-macrophage colony-stimulating factor: increased efficacy and reduced toxicity when given subcutaneously.

  1996cited by this paper
• Use of cytokines in the treatment of acute myelocytic leukemia: a critical review.

  1996cited by this paper
• Randomized trial of recombinant human granulocyte-macrophage colony-stimulating factor in pediatric patients receiving intensive myelosuppressive chemotherapy.

  1996cited by this paper
• Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.

  1996cited by this paper
• Transfer of granulocyte-macrophage colony-stimulating factor gene to rat lung induces eosinophilia, monocytosis, and fibrotic reactions.

  1996cited by this paper
• GM-CSF accelerates neutrophil recovery after autologous hematopoietic stem cell transplantation.

  1996cited by this paper
• Dose-dependent mobilisation of haematopoietic progenitor cells in healthy volunteers receiving glycosylated rHuG-CSF.

  1996cited by this paper
• Gene transfer for cytokine functional studies in the lung: the multifunctional role of GM‐CSF in pulmonary inflammation

  1996cited by this paper
• Antitumor and accessory immune activities of peripheral blood stem cells mobilized with granulocyte-macrophage colony-stimulating factor.

  1996cited by this paper
• The pulmonary alveolar proteinosis in granulocyte macrophage colony- stimulating factor/interleukins 3/5 beta c receptor-deficient mice is reversed by bone marrow transplantation

  1996cited by this paper
• Aerosol delivery of interleukin 2 liposomes is nontoxic and biologically effective: canine studies.

  1996cited by this paper
• Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.

  1996cited by this paper
• Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous Done marrow after high‐dose chemotherapy

  1995cited by this paper
• Hematopoietic growth factors. Defining the appropriate clinical role in multimodality cancer therapy.

  1995cited by this paper
• Needed: qualitative improvement in antisarcoma therapy.

  1995cited by this paper
• A randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490).

  1995cited by this paper
• Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: a prospective phase III randomized study of the Southwest Oncology Group.

  1995cited by this paper
• Influence of in vivo administration of GM-CSF and G-CSF on monocyte cytotoxicity.

  1995cited by this paper
• Effects of granulocyte‐macrophage colony stimulating factor produced in Chinese hamster ovary cells (regramostim), Escherichia coli (molgramostim) and yeast (sargramostim) on priming peripheral blood progenitor cells for use with autologous bone marrow after high‐dose chemotherapy

  1995cited by this paper
• Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.

  1994cited by this paper
• Operating characteristics of 18 different continuous-flow jet nebulizers with beclomethasone dipropionate liposome aerosol.

  1994cited by this paper
• Chemotherapeutic approaches to soft tissue sarcomas.

  1994cited by this paper
• Cytotoxic drugs plus subcutaneous granulocyte-macrophage colony-stimulating factor: can molgramostim enhance antisarcoma therapy?

  1994cited by this paper
• Involvement of granulocyte-macrophage colony-stimulating factor in pulmonary homeostasis.

  1994cited by this paper
• Effects of Route and Formulation on Clinical Pharmacokinetics of Interleukin-2

  1994cited by this paper
• Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor.

  1993cited by this paper
• Adverse effects of molgramostim in marrow transplant recipients.

  1993cited by this paper
• Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.

  1993cited by this paper
• Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity.

  1993influential reference
• Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design.

  1993cited by this paper
• Effects of continuous high dose rhgm‐csf infusion on human monocyte activity

  1993cited by this paper
• Clinical properties of yeast-derived versus Escherichia coli-derived granulocyte-macrophage colony-stimulating factor

  1993cited by this paper
• Granulocyte-macrophage colony-stimulating factor given before dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP).

  1993cited by this paper
• The effect of aerosolized recombinant human granulocyte macrophage colony-stimulating factor on lung leukocytes in nonhuman primates.

  1992cited by this paper
• Recombinant granulocyte-macrophage colony-stimulating factor (rGM-CSF). A review of its pharmacological properties and prospective role in the management of myelosuppression.

  1992cited by this paper
• Granulocyte‐macrophage colony‐stimulating factor: Preliminary observations on the influences of dose, schedule, and route of administration in patients receiving cyclophosphamide and carboplatin

  1992cited by this paper
• Generalized Linear Models

  1992cited by this paper
• Granulocyte macrophage colony-stimulating factor

  1991cited by this paper
• Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma.

  1990cited by this paper
• Hematopoietic growth factors. Biology and clinical applications.

  1989cited by this paper
• Local continuous high dose interleukin 2: a new therapeutic model for the treatment of advanced bladder carcinoma.

  1989cited by this paper
• Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage.

  1987cited by this paper
• Longitudinal data analysis using generalized linear models

  1986cited by this paper
• Generalized Linear Models

  1984cited by this paper

• Inhalable nanomedicine for lung cancer treatment

  2024cites this paper
• Cytokine screening identifies TNF to potentially enhance immunogenicity of pediatric sarcomas

  2024cites this paper
• Repeated inhalation of GM-CSF by nonhuman primates induces bronchus-associated lymphoid tissue along the lower respiratory tract

  2024cites this paper
• Nebulised sargramostim in pulmonary alveolar proteinosis

  2022influential citation
• Sarcomas of Bone and Soft Tissues in Children and Adolescents

  2021cites this paper
• New therapies for nontuberculous mycobacterial lung infection

  2021cites this paper
• Sargramostim and immune checkpoint inhibitors: combinatorial therapeutic studies in metastatic melanoma.

  2021cites this paper
• Identification of a 7-mRNA signature as a prognostic biomarker in pediatric osteosarcoma

  2020cites this paper
• Pharmacotherapy options in pulmonary alveolar proteinosis.

  2020cites this paper
• Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.

  2020cites this paper
• Immunotherapy for Pediatric Sarcomas

  2020cites this paper
• Immunotherapy for Pediatric Solid Tumors

  2020cites this paper
• Targeting Tumor-Associated Macrophages in the Pediatric Sarcoma Tumor Microenvironment

  2020cites this paper
• Immunotherapy in Pediatric Solid Tumors—A Systematic Review

  2019cites this paper
• Inhaled Antibiotics for Mycobacterial Lung Disease

  2019cites this paper
• Polymeric Nanoparticle-Based Drug/Gene Delivery for Lung Cancer

  2019cites this paper
• Inhaled granulocyte–macrophage colony-stimulating factor for Mycobacterium abscessus in cystic fibrosis

  2018cites this paper
• Inhalable particulate drug delivery systems for lung cancer therapy: Nanoparticles, microparticles, nanocomposites and nanoaggregates.

  2018cites this paper
• Interested in publishing with us ? Contact book

  2018cites this paper
• Targeting lung cancer by identifying genes associated with resistance and developing lipid based nanodispersions for the inhalation delivery of therapeutic payloads

  2018cites this paper
• Current treatment landscape and emerging management options for extremity sarcoma

  2018cites this paper
• Novel Fusion Protein IL-12/Fas TI for Cancer Immunogene Therapy

  2018cites this paper
• PROBLEMS AND PROSPECTS OF INHALATION APPLICATION OF PEPTIDE AND PROTEIN COMPOUNDS AS POTENTIAL MEDICAL RADIATION PROTECTIVE AGENTS

  2018cites this paper
• INTERLEUKIN 12 / FASTI : A Novel BiFunctional Fusion Protein for Cancer Immunogene Therapy

  2018cites this paper
• Primary metastatic osteosarcoma: results of a prospective study in children given chemotherapy and interleukin-2

  2017cites this paper
• XXIX MED / 04 Cancer therapy through TLR-induced local innate immunity activation and block of immune checkpoints or suppressive cells

  2017cites this paper
• Strategies and developments of immunotherapies in osteosarcoma.

  2016cites this paper
• Inhaled anticancer agents

  2016cites this paper
• Stimulatory versus suppressive effects of GM-CSF on tumor progression in multiple cancer types

  2016cites this paper
• Toxicity and Pharmacokinetic Studies of Aerosolized Clinical Grade Azacitidine.

  2016cites this paper
• Non-surgical Treatment of Pediatric Bone Sarcomas

  2016cites this paper
• Pulmonary alveolar proteinosis and granulocyte/macrophage-colony stimulating factor (GM-CSF) inhalation

  2016cites this paper
• Strategies and developments of immunotherapies in osteosarcoma (Review)

  2016cites this paper
• Chemotherapy, Irradiation, and Surgery for Function-preserving Curative Therapy of Primary Extremity Soft Tissue Sarcomas: Initial Treatment With I-MAP and Inhalation GM-CSF During Preoperative Irradiation and Postoperatively

  2016cites this paper
• Mouse interleukin-12/FasTI: A novel bi-functional fusion protein for cancer immuno/gene therapy.

  2016cites this paper
• Present Advances and Future Perspectives of Molecular Targeted Therapy for Osteosarcoma

  2016cites this paper
• Bone Sarcomas in Pediatrics: Progress in Our Understanding of Tumor Biology and Implications for Therapy

  2015cites this paper
• Aerosol Delivery in the Treatment of Lung Cancer.

  2015cites this paper
• Nanotechnology approaches for inhalation treatment of lung diseases.

  2015cites this paper
• Toward a Drug Development Path That Targets Metastatic Progression in Osteosarcoma

  2014influential citation
• Long-Term Inhaled Granulocyte Macrophage–Colony-Stimulating Factor in Autoimmune Pulmonary Alveolar Proteinosis: Effectiveness, Safety, and Lowest Effective Dose

  2014cites this paper
• The use of amino acids to prepare physically and conformationally stable spray-dried IgG with enhanced aerosol performance.

  2014cites this paper
• New Medical/Biologic Paradigms in the Treatment of Bone Tumors

  2014cites this paper
• Duration of benefit in patients with autoimmune pulmonary alveolar proteinosis after inhaled granulocyte-macrophage colony-stimulating factor therapy.

  2014cites this paper
• Inhaled lipid cisplatin (ILC) in the treatment of patients with relapsed/progressive osteosarcoma metastatic to the lung

  2013cites this paper
• The Current and Future Therapies for Human Osteosarcoma.

  2013cites this paper
• Long Term Follow Up: Phase I Trial of bi-shRNA furin/GMCSF DNA/Autologous Tumor Cell Immunotherapy (FANG) in Advanced Cancer

  2013cites this paper
• Inhaled gene therapy in lung cancer: proof-of-concept for nano-oncology and nanobiotechnology in the management of lung cancer.

  2013cites this paper
• Future directions for pediatric and young adult bone sarcoma.

  2013cites this paper
• colony-stimulating factor gene transfer - cyclophosphamide: restoration by local granulocyte macrophage Reduced tissue macrophage population in the lung by anticancer agent

  2013cites this paper
• Current Therapeutic Strategies and Novel Approaches in Osteosarcoma

  2013cites this paper
• Anti‐tumor activity of CpG‐ODN aerosol in mouse lung metastases

  2013cites this paper
• New targets and approaches in osteosarcoma.

  2013cites this paper
• Chemotherapy in Osteosarcoma

  2012cites this paper
• Resistance--the true face of biological defiance.

  2012cites this paper
• Acute radiation syndrome (ARS) – treatment of the reduced host defense

  2012cites this paper
• Medication for the treatment of lung cancer : Emphasis on aerosolized chemotherapy

  2012cites this paper
• Direct evidence that GM-CSF inhalation improves lung clearance in pulmonary alveolar proteinosis.

  2012cites this paper
• Understanding drug resistance to biologic therapy Resistance — the true face of biological defiance

  2012cites this paper
• The immunomodulatory effect of inhaled granulocyte-macrophage colony-stimulating factor in cystic fibrosis. A new treatment paradigm

  2012cites this paper
• Induction of Specific Cellular and Humoral Responses Against Renal Cell Carcinoma After Combination Therapy With Cryoablation and Granulocyte-Macrophage Colony Stimulating Factor: A Pilot Study

  2011cites this paper
• The Airways: A Promising Route for the Pulmonary Delivery of Anticancer Agents

  2011cites this paper
• Inhaled granulocyte/macrophage-colony stimulating factor as therapy for pulmonary alveolar proteinosis.

  2010cites this paper
• Immune-based therapeutics for pediatric cancer

  2010cites this paper
• Animal Models of Malignant Primary Bone Tumors and Novel Therapeutic Approaches

  2010cites this paper
• GM-CSF Therapy for Pulmonary Alveolar Proteinosis.

  2010cites this paper
• Inhaled Granulocyte-Macrophage Colony Stimulating Factor for First Pulmonary Recurrence of Osteosarcoma: Effects on Disease-Free Survival and Immunomodulation. A Report From the Children's Oncology Group

  2010cites this paper
• Molecularly targeted therapy for osteosarcoma: Where do we go from here?

  2010cites this paper
• Osteosarcoma: a review of diagnosis, management, and treatment strategies.

  2010cites this paper
• Drug-induced and Iatrogenic Respiratory Disease

  2010cites this paper
• GM-CSF pathway correction in pulmonary alveolar proteinosis

  2010cites this paper
• UNIVERSITÁ DEGLI STUDI DI MILANO FACOLTÁ DI MEDICINA E CHIRURGIA

  2010cites this paper
• Treatment of systemic diseases by inhalation of biomolecule aerosols.

  2009cites this paper
• Immune approaches to treating osteosarcoma

  2009cites this paper
• Novel therapeutic agents for osteosarcoma

  2009cites this paper
• Treatment of Pediatric Bone Sarcomas

  2009cites this paper
• Inhaled therapeutics for prevention and treatment of pneumonia

  2009influential citation
• Non-surgical treatment of pulmonary and extra-pulmonary metastases.

  2009cites this paper
• Nanocapsules lipidiques de paclitaxel et cancer bronchique : premières données d'efficacité et de toxicité chez la souris et méthodes d'aérosolisation à partir de lots précliniques

  2009cites this paper
• Inhaledtherapeuticsfor preventionandtreatmentof pneumonia

  2009cites this paper
• WT1 gene silencing by aerosol delivery of PEI–RNAi complexes inhibits B16-F10 lung metastases growth

  2009cites this paper
• Translation of new cancer treatments from pet dogs to humans

  2008cites this paper
• Disease guided optimization of the respiratory delivery of microparticulate formulations.

  2008cites this paper
• Therapy for Osteosarcoma

  2008cites this paper
• Systemic treatment by inhalation of macromolecules--principles, problems, and examples.

  2008cites this paper
• Disease guided optimization of the respiratory delivery of microparticulate formulations

  2008cites this paper
• Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma)

  2008cites this paper
• A Dose-Escalation Study of Aerosolized Sargramostim in the Treatment of Metastatic Melanoma: An NCCTG Study

  2008cites this paper
• Novel bone cancer drugs: investigational agents and control paradigms for primary bone sarcomas (Ewing's sarcoma and osteosarcoma).

  2008cites this paper
• Aerodynamical, Immunological and Pharmacological Properties of the Anticancer Antibody Cetuximab Following Nebulization

  2008cites this paper
• Current concepts on the surgical and medical management of osteosarcoma

  2008cites this paper
• Intranasal Granulocyte-Macrophage Colony-Stimulating Factor Reduces the Aspergillus Burden in an Immunosuppressed Murine Model of Pulmonary Aspergillosis

  2007cites this paper
• NEONATAL IMMUNE MODULATION TO IMPROVE PNEUMOCYSTIS CLEARANCE

  2007influential citation
• Therapeutic efficacy of aerosolized liposome-encapsulated nubiotic against pulmonary Pseudomonas aeruginosa infection

  2007cites this paper
• p53 Aerosol Formulation with Low Toxicity and High Efficiency for Early Lung Cancer Treatment

  2007cites this paper
• Phase I Study of Aerosolized SLIT Cisplatin in the Treatment of Patients with Carcinoma of the Lung

  2007cites this paper
• Combined oncolytic and vaccination activities of parvovirus H-1 in a metastatic tumor model.

  2007cites this paper
• Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies

  2007cites this paper
• Aerosol granulocyte-macrophage colony-stimulating factor for pulmonary alveolar proteinosis

  2006cites this paper
• Biology and therapy of solid tumors in childhood

  2006cites this paper